- Joined
- 27 June 2010
- Posts
- 4,335
- Reactions
- 368
Nexsen Limited is a nanobiotechnology company, dedicated to the development of proprietary biosensing platforms for rapid, high precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications.
Nexsen’s most advanced product is the GBS Rapid Sensor – a diagnostic for the detection of human Group B Streptococcus (GBS) in expectant mothers.
The GBS Rapid Sensor product utilises innovative nano-biotechnology to enable timely diagnostics of these important pathogenic bacteria in expectant mothers. This innovation represents a substantial advancement in primary healthcare, offering a rapid alternative to the conventional, pathology-based diagnostic processes currently in use at weeks 36-37 of pregnancy for this critical healthcare need.
Nexsen's GBS Rapid Sensor project has received substantial support through a prestigious ~$7.7 million Cooperative Research Centres Projects (CRC-P) Commonwealth grant, which includes $3 million in direct Commonwealth cash funding. Receiving a CRC-P grant in a highly competitive process reflects the project’s significance and the confidence of the Australian Government in its potential to address a critical healthcare challenge.
This funding supports an already approved human clinical trial for the GBS Rapid Sensor, planned to commence in Q4 CY2025. Regulatory pathways for a commercial rollout have been mapped, with the USA, India, Malaysia, the EU, and Australia as initial target markets.
It is anticipated that NXN will list on the ASX during October 2025.
www.nexsen.bio
Nexsen’s most advanced product is the GBS Rapid Sensor – a diagnostic for the detection of human Group B Streptococcus (GBS) in expectant mothers.
The GBS Rapid Sensor product utilises innovative nano-biotechnology to enable timely diagnostics of these important pathogenic bacteria in expectant mothers. This innovation represents a substantial advancement in primary healthcare, offering a rapid alternative to the conventional, pathology-based diagnostic processes currently in use at weeks 36-37 of pregnancy for this critical healthcare need.
Nexsen's GBS Rapid Sensor project has received substantial support through a prestigious ~$7.7 million Cooperative Research Centres Projects (CRC-P) Commonwealth grant, which includes $3 million in direct Commonwealth cash funding. Receiving a CRC-P grant in a highly competitive process reflects the project’s significance and the confidence of the Australian Government in its potential to address a critical healthcare challenge.
This funding supports an already approved human clinical trial for the GBS Rapid Sensor, planned to commence in Q4 CY2025. Regulatory pathways for a commercial rollout have been mapped, with the USA, India, Malaysia, the EU, and Australia as initial target markets.
It is anticipated that NXN will list on the ASX during October 2025.
Rapid, lab-grade accuracy at the point of care | Nexsen
Nexsen delivers rapid, lab-quality diagnostics at the point of care. Discover our innovative platform designed to transform healthcare delivery.
www.nexsen.bio
